NO20042074L - Makrolider inneholdende farmasoytiske sammensetninger - Google Patents

Makrolider inneholdende farmasoytiske sammensetninger

Info

Publication number
NO20042074L
NO20042074L NO20042074A NO20042074A NO20042074L NO 20042074 L NO20042074 L NO 20042074L NO 20042074 A NO20042074 A NO 20042074A NO 20042074 A NO20042074 A NO 20042074A NO 20042074 L NO20042074 L NO 20042074L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
containing pharmaceutical
macrolides containing
macrolides
compositions
Prior art date
Application number
NO20042074A
Other languages
English (en)
Norwegian (no)
Inventor
Josef Gottried Meingassner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127341A external-priority patent/GB0127341D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042074L publication Critical patent/NO20042074L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20042074A 2001-10-23 2004-05-19 Makrolider inneholdende farmasoytiske sammensetninger NO20042074L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0125443.2A GB0125443D0 (en) 2001-10-23 2001-10-23 Organic Compounds
GB0127341A GB0127341D0 (en) 2001-11-14 2001-11-14 Organic compounds
PCT/EP2002/011799 WO2003035068A1 (en) 2001-10-23 2002-10-22 Macrolides containing pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20042074L true NO20042074L (no) 2004-05-19

Family

ID=26246689

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042074A NO20042074L (no) 2001-10-23 2004-05-19 Makrolider inneholdende farmasoytiske sammensetninger

Country Status (19)

Country Link
US (1) US7259170B2 (pl)
EP (1) EP1439838A1 (pl)
JP (1) JP2005509634A (pl)
KR (2) KR100978971B1 (pl)
CN (1) CN1307993C (pl)
AU (1) AU2002346859C1 (pl)
BR (1) BR0213463A (pl)
CA (1) CA2458690C (pl)
EC (1) ECSP045086A (pl)
GB (1) GB0125443D0 (pl)
HU (1) HUP0402108A3 (pl)
IL (1) IL160973A0 (pl)
MX (1) MXPA04003738A (pl)
NO (1) NO20042074L (pl)
NZ (1) NZ532412A (pl)
PL (1) PL368533A1 (pl)
RU (1) RU2321402C2 (pl)
WO (1) WO2003035068A1 (pl)
ZA (1) ZA200401711B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209474A (pt) * 2001-05-09 2006-02-07 Novartis Ag Métodos para imunomodulação seletiva
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921934T2 (de) 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
DK0427680T3 (da) * 1989-11-09 1995-12-18 Sandoz Ltd Heteroatom-holdige cykliske forbindelser
US5352671A (en) * 1989-11-09 1994-10-04 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB2252041A (en) 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
EP0576605A4 (en) * 1991-03-19 1994-06-08 Vithal J Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
GB9203636D0 (en) * 1992-02-19 1992-04-08 Lucas Ind Plc Fuel pumping apparatus
DE69321823T2 (de) 1992-10-21 1999-06-02 Taito Co., Ltd., Tokio/Tokyo 2-amino-1, 3- propandiolverbindung und immunosuppressium
CA2156065A1 (en) 1993-03-17 1994-09-29 Rolf Wagner Macrocyclic amide and urea immunomodulators
US5590460A (en) * 1994-07-19 1997-01-07 Tessera, Inc. Method of making multilayer circuit
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
GB9521322D0 (en) 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
ES2240868T3 (es) 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
GB9713730D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
GB0003932D0 (en) 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
AU2002249826A1 (en) 2000-12-22 2002-07-30 Avantec Vascular Corporation Delivery of therapeutic capable agents

Also Published As

Publication number Publication date
CA2458690C (en) 2011-01-25
RU2004116067A (ru) 2005-04-20
HUP0402108A2 (hu) 2005-02-28
EP1439838A1 (en) 2004-07-28
HUP0402108A3 (en) 2008-02-28
WO2003035068A1 (en) 2003-05-01
CA2458690A1 (en) 2003-05-01
KR20090114483A (ko) 2009-11-03
MXPA04003738A (es) 2004-07-23
GB0125443D0 (en) 2001-12-12
KR20040052250A (ko) 2004-06-22
BR0213463A (pt) 2004-11-09
IL160973A0 (en) 2004-08-31
CN1307993C (zh) 2007-04-04
KR100978971B1 (ko) 2010-08-30
US7259170B2 (en) 2007-08-21
CN1575173A (zh) 2005-02-02
ZA200401711B (en) 2004-10-21
NZ532412A (en) 2006-01-27
RU2321402C2 (ru) 2008-04-10
AU2002346859B2 (en) 2006-03-02
US20040192716A1 (en) 2004-09-30
ECSP045086A (es) 2004-06-28
AU2002346859C1 (en) 2008-07-10
PL368533A1 (pl) 2005-04-04
JP2005509634A (ja) 2005-04-14

Similar Documents

Publication Publication Date Title
FI20011478L (fi) Farmaseuttinen koostumus
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
ITMI20010748A0 (it) Composizioni farmaceutiche
DK1524266T3 (da) Farmaceutisk sammensætning
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
NO20033785L (no) Farmasöytisk formulering
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE200300589A (et) Ravimkoostised
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
NO20035627D0 (no) Farmasöytisk formulering
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A0 (fi) Farmaseuttinen koostumus
DK1425005T3 (da) Farmaceutisk sammensætning indeholdende lumiracoxib
NO20031095D0 (no) Farmasöytiske sammensetninger
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
EE200200689A (et) Ravimkoostised
EP1413314A4 (en) MEDICAL COMPOSITIONS
FI5468U1 (fi) Farmaseuttinen koostumus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application